Clinical trial NCT03473951: The Relationship Among, Serum Uric Acid, Left Ventricular Hypertrophy and Metabolic Syndrome
Official title: The Dose-response Effect of Serum Uric Acid on the Prevalence and Electrocardiographic Left Ventricular Hypertrophy in the Apparently Healthy Individuals
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Hyperuricemia
Healthy
Keywords: Hyperuricemia
Metabolic syndrome
Left ventricular hypertrophy
Lead sponsor: National Defense Medical Center, Taiwan
Sponsor class: OTHER
First posted: 2018-03-22
Enrollment: 18000
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Apparently healthy individuals routinely underwent the annual health exam.

Brief summary: Hyperuricemia is associated with the prevalence of metabolic syndrome and cardiovascular risks in diverse of the population. Whether the dose-response effects on the prevalence of metabolic syndrome and cardiometabolic risks is unclear. The present study is conducted to investigate the relationship between serum uric acid and the prevalence metabolic syndrome and left ventricular hypertrophy.

Detailed description: Apparently healthy individuals with an estimated screening number of approximately twenty-thousand individuals undergo an annual health exam in the investigators' hospital. The routine exam includes measurements of body height, body weight, blood pressure, visual and acoustic acuity, physical examinations, basic blood tests, urine analyses, chest radiography, and electrocardiography. The blood tests were performed after individuals fasted for at least eight hours. Individuals with any abnormal results underwent a clinical examination at an outpatient department for safety issues, ensuring the accuracy of the data. All data were registered prospectively. The investigators retrospectively collected data from the annual exam.

Eligibility criteria: Inclusion Criteria:

* Individuals with ages of 20-65 years underwent the annual health exam at the investigators' hospital.

Exclusion Criteria:

* The individual had no data to define metabolic syndrome, including waist circumference, office blood pressure, serum uric acid, triglyceride, high-density lipoprotein cholesterol, fasting glucose.

Primary outcomes:
measure: The prevalence of metabolic syndrome
timeFrame: 1 day
Secondary outcomes:
measure: Left ventricular hypertrophy - Cornell voltage criteria.
timeFrame: 1 day
measure: Left ventricular hypertrophy - Cornell voltage product.
timeFrame: 1 day
measure: Left ventricular hypertrophy - Sokolow-Lyon criteria.
timeFrame: 1 day
measure: Left ventricular hypertrophy - Minnesota Code electrocardiographic classification.
timeFrame: 1 day
measure: Left ventricular hypertrophy - composite of Cornell voltage criteria, Cornell voltage product, Sokolow-Lyon criteria, Minnesota Code electrocardiographic classification.
timeFrame: 1 day
measure: brief symptom rating scale-5
timeFrame: 1 day
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Tri-service General Hospital, songshan branch
state: Songshan Dist.
Study officials:
References:
citation: Tu CM, Wei TE, Tseng GS, Chen CC, Liu CW. Serum uric acid is associated with incident metabolic syndrome independent of body shape index and body roundness index in healthy individuals. Nutr Metab Cardiovasc Dis. 2021 Oct 28;31(11):3142-3151. doi: 10.1016/j.numecd.2021.07.008. Epub 2021 Jul 24.
citation: Liu CW, Ke SR, Tseng GS, Wu YW, Hwang JJ. Elevated serum uric acid is associated with incident hypertension in the health according to various contemporary blood pressure guidelines. Nutr Metab Cardiovasc Dis. 2021 Apr 9;31(4):1209-1218. doi: 10.1016/j.numecd.2021.01.003. Epub 2021 Jan 12.
citation: Liu CW, Chen KH, Tseng CK, Chang WC, Wu YW, Hwang JJ. The dose-response effects of uric acid on the prevalence of metabolic syndrome and electrocardiographic left ventricular hypertrophy in healthy individuals. Nutr Metab Cardiovasc Dis. 2019 Jan;29(1):30-38. doi: 10.1016/j.numecd.2018.10.001. Epub 2018 Oct 16.